A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Cancer Genetics Education Program

Cancer Genetics Education Program
The Division of Clinical Cancer Genetics at City of Hope offers educational coursesand self-teaching tools forprofessionals in the fields of cancer and cancer genetics.ThisCancer Genetics Education Program (CGEP) is supported inpart by funding fromthe NCI (IRC4CA153828-01 andIR25CA112486).
 
Dramatic advances in our understanding of the genetic basis for cancer have led to the development of new technologies and tools for genetic cancer risk assessment. The Cancer Genetics Education Program at City of Hope offers a series of comprehensive learning tools designed to enhance the education of primary care physicians and clinical oncology professionals on the topics of cancer genetics and cancer risk assessment, and their application to patient care. Through a series of educational courses, workshops, seminars, newsletters and a direct, interactive electronic communications network, professionals can be tutored in the latest information on cancer molecular genetics, the fundamentals of obtaining an adequate family history, understanding genetic cancer risk assessment, ethical and legal complexities of genetic testing, and other current/timely topics.
 
Cancer Genetics Career Development Program
City of Hope offers an innovative  Cancer Genetics Career Development Program (CGCDP) whichprovides interdisciplinary training focused on cancer genetics and cancer prevention control research. The Traineeship is open to three applicants per year.
 
Intensive Course in Cancer Risk Assessment
City of Hope's Division of Clinical Cancer Genetics offers an annual CME/CEU-accredited multi-modal intensive course to address the need for professional training in clinical cancer genetics and research collaboration for community-based clinicians.
 
Clinical Cancer Genetics Community of Practice
City of Hope CCG Community of Practice brings cancer genetics practitioners from diverse practice settings together for professional learning, enduring patient-centered support and dynamic community-based research collaborations to promote quality care and improved patient outcomes across the U.S. and internationally.

CCGCRN

The Clinical Cancer Genetics Community Research Network (CCGCRN) is a large research group of over 40 collaborating sites in the United States, Mexico, and South America. The cornerstone of this network is the City of Hope Hereditary Cancer Research Registry (Molecular Genetic Studies in Cancer Patients and their Relatives; IRB# 96144), a prospective research registry protocol initiated at the City of Hope in 1996, by Principal Investigator Jeffrey Weitzel, MD. The registry serves as a biospecimen repository with personal and family medical history, psycho-social and clinical follow-up data, and 4-generation family pedigree. As members of the CCGCRN, research collaborators can use the message board and forums to post questions and communicate with other members in the network.
 
 
City of Hope CCGCRN Objectives
 
  • To create common and complimentary community-based, locally relevant cancer genomics/genetics research agendas, especially among underserved outreach clinics
  • To address geographic, socioeconomic, and ethnic disparities in cancer genetics healthcare and research participation
  • To leverage next-generation genomic technologies to engage/promote hereditary cancer research and clinical translation globally, with a focus in Latin America
 
General questions or comments may be submitted via e-mail to: ccgcrn@coh.org
 
 
General links of interest:
 
Links for members:

Working Group

Clinical Cancer Genetics (CCG) Working Group is a CME-accredited interdisciplinary cancer genetics case conference series conducted each week by the City of Hope clinical team. CSPPN and affiliated clinicians across the U.S. present cases from their community practices via web conferencing for discussion and recommendations on risk assessment, surveillance, risk management and identification of research eligibility for cases covering the full spectrum of hereditary cancer.

Cancer Genetics Community Link

The Cancer Genetics Community Discussion Board is a Web-based discussion board for collaborative, interdisciplinary practice-based support and continuing professional learning. CCG Community of Practice members are encouraged to post and respond to case-based questions and share resources with a growing, multidisciplinary network of professionals engaged in the practice of clinical cancer genetics. Messages are posted and archived under topic-specific forums, allowing members to search for information by topic of interest.
 
Case Consultation Questions

Breast/Ovarian Cancers (Uninformative BRCA Test Results)

Breast/Ovarian Cancers (Testing)

Breast/Ovarian Cancers (Probability/Empiric Risks)

Breast/Ovarian Cancers (Risk Management)

Breast/Ovarian Cancers (Hormone Replacement Therapy)

Male Breast Cancers

Gastrointestinal Cancers (Lynch Related)

Gastrointestinal Cancers (Polyposis Syndromes)

Gastrointestinal Cancers (Non-Colorectal)

Gastrointestinal Cancers (Risk Management)

Genitourinary Cancer

Genodermatoses

Endocrine Neoplasias

Pediatric Cancers

ELSI-Ethical, Legal, Social Issues

 

Clinical Resources

Progeny/Pedigree Drawing Issues

 

Clinical Cancer Genetics Working Group

CCG Working Group Case Conferences

 

Comments/Suggestions

Suggestion/Comment Box

 

Clinical Cancer Genetics Education Team

Clinical Cancer Genetics Events Calendar

Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
CCG Newsletter: Closing the Loop
View the current issue: CCG Newsletter
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
NEWS & UPDATES
  • Counter-intuitive though it might seem, a prostate cancer diagnosis shouldn’t always lead to immediate prostate cancer treatment. Although prostate cancer is the second-leading cancer killer of men, behind lung cancer, and causes more than 29,000 deaths in the U.S. each year, in many cases, the tumors are...
  • Radiology is one of the cornerstones of any hospital. It is a key diagnostic branch of medicine essential for the initial diagnosis of many diseases and has an important role in monitoring a patient’s treatment and predicting outcome. Radiology is the specialty considered to be both the “eyes” and “ears” of med...
  • Donating blood and platelets saves lives. We all know this. Yet every summer, potential blood donors become distracted by vacations and schedule changes. As a result, blood donations fall dramatically across the nation, leaving hospitals frantically trying to bring in much-needed blood for their patients. Earli...
  • To be a great cancer hospital, you need a great oncology program. Just ask City of Hope – and Becker’s Hospital Review. The health care publishing industry stalwart, described as the “leading hospital magazine for hospital business news and analysis for hospital and health system executives,” recently selected ...
  • Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year. With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Ag...
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...